Sanjeev Mittal, MD
Nephrology · Memphis, TNNPI 1689603102
Payments from drug & device makers
Across 447 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Otsuka America Pharmaceutical, Inc.$1K
- AstraZeneca$975
- Vifor Pharma, Inc.$611
- Bayer$606
- Fresenius USA Marketing, Inc.$588
- plus $5K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $4,035 |
| Otsuka America Pharmaceutical, Inc. | 49 | $1,049 |
| AstraZeneca | 59 | $975 |
| Vifor Pharma, Inc. | 31 | $611 |
| Bayer | 37 | $606 |
| Fresenius USA Marketing, Inc. | 39 | $588 |
| OPKO Pharmaceuticals, LLC | 30 | $568 |
| Aurinia Pharma U.S., Inc. | 16 | $508 |
| Travere Therapeutics, Inc. | 24 | $414 |
| Amgen(2 entities) | 20 | $400 |
| Mallinckrodt Hospital Products Inc. | 14 | $350 |
| ANI Pharmaceuticals, Inc. | 17 | $334 |
| Akebia Therapeutics Inc | 20 | $314 |
| Ultragenyx Pharmaceutical Inc. | 15 | $311 |
| Lilly USA, LLC | 11 | $301 |
| Novartis | 9 | $277 |
| Ardelyx, Inc. | 8 | $228 |
| Calliditas Therapeutics US Inc. | 7 | $165 |
| Ipsen Biopharmaceuticals, Inc | 1 | $111 |
| Veloxis Pharmaceuticals, Inc. | 1 | $96 |
| Boehringer Ingelheim | 4 | $87 |
| Arbor Pharmaceuticals, Inc. | 5 | $79 |
| Mallinckrodt Enterprises LLC | 3 | $61 |
| Lundbeck LLC | 2 | $42 |
| Baxter Healthcare | 1 | $31 |
| Novo Nordisk | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Sanofi | 1 | $19 |
| Shield Therapeutics Inc | 1 | $17 |
| Nuwellis, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$12,673 in reported general payments places this provider in the 80th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Memphis
- Wael HusseinMemphis$912K
- Lekha GeorgeMemphis$164K
- Omar DavisMemphis$118K
- Omar HamzeMemphis$90K
- Natarsha GrantMemphis$53K
- Marc StegmanMemphis$41K
- Robert CanadaMemphis$20K
- Minesh PathakMemphis$14K
- Miklos MolnarMemphis$12K
- Vasanthi BalaramanMemphis$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.